← All trials
NCT01150942
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2010
- Primary completion
- Sep 1, 2012
- Completion date
- Feb 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 205
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Boryung Pharmaceutical CompanyLead sponsor
- Seoul National UniversityOverall official - principal investigator
- Inha UniversityCollaborator
- Inje UniversityCollaborator
- Korea Cancer Center HospitalCollaborator
- Catholic University of KoreaCollaborator
- Sungkyunkwan UniversityCollaborator
- Seoul National UniversityCollaborator
- Gachon UniversityCollaborator
- Kyung Hee UniversityCollaborator
- Wonju Christian HospitalCollaborator
- Ewha Womans UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.